Clinical Report: Can Shorter TB Prevention Regimens Work?

Overview

A modified 3-month rifapentine plus isoniazid regimen was found to be noninferior to the standard 9-month isoniazid regimen for preventing tuberculosis in patients with rheumatic diseases and latent infection. The study demonstrated a favorable safety profile and similar treatment completion rates.

Background

Tuberculosis (TB) remains a significant global health concern, particularly among high-risk populations such as patients with rheumatic diseases. Traditional preventive regimens, such as the 9-month isoniazid treatment, can be burdensome and associated with adverse effects. Shorter regimens like the 3-month rifapentine plus isoniazid may offer a more effective and tolerable alternative, warranting investigation.

Data Highlights

Key Findings

• The 3-month rifapentine plus isoniazid regimen (3HP-PUMCH) showed a cumulative TB rate of 0% compared to 1.2% in the 9-month isoniazid regimen (9H).
• Adverse drug reactions were reported in 9.6% of the 3HP-PUMCH group versus 15% in the 9H group.
• Hepatotoxicity occurred in 4.4% of patients receiving 3HP-PUMCH, significantly lower than the 10.4% in the 9H group.
• Treatment completion rates were similar, with 89.6% for 3HP-PUMCH and 91.2% for 9H.
• The study was conducted with 536 patients aged 18 to 70 years with high-risk rheumatic diseases.
• Further large-scale trials are needed to confirm these findings across diverse settings.

Clinical Implications

The findings suggest that the 3-month rifapentine plus isoniazid regimen may be a viable alternative to the standard 9-month regimen for TB prevention in patients with rheumatic diseases. This shorter regimen could reduce treatment burden and drug toxicity, potentially improving adherence and outcomes in this high-risk population.

Conclusion

The study provides high-level evidence supporting the use of a shorter TB preventive treatment regimen in patients with rheumatic diseases. Further research is necessary to validate these results and inform clinical guidelines.

References

1. Lifan Zhang, MD, et al., eClinicalMedicine, 2023 -- Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial
2. conexiant — The 18-Month MDR-TB Regimen Has a Successor
3. Open Forum Infectious Diseases — Evaluation of a Novel All-Oral Short-Term Treatment for Multidrug-Resistant Tuberculosis: Findings from a Semi-Randomized Controlled Trial in China
4. The Journal of Infectious Diseases — Intranasal Supplementation of an Ultra-Rapid Oral Drug Regimen Enhances Relapse-Free Tuberculosis Cure Rates in Murine Models
5. Open Forum Infectious Diseases — Recurrence and Development of Resistance in Patients Undergoing Innovative Short-Term Treatments for Multidrug-Resistant Tuberculosis in the United States, 2022–2024
6. Treatment for Latent Tuberculosis Infection | Tuberculosis (TB) | CDC
7. Rifapentine and isoniazid for latent tuberculosis - PubMed
8. Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial - ScienceDirect